Shanghai MicroPort MedBot (Group) Co., Ltd.
上海微创医疗机器人(集团)股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT – TOUMAI COMMERCIAL INSTALLATIONS EXCEEDING 200 UNITS WORLDWIDE

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders of the Company (the "**Shareholders**") and potential investors the updates on the latest business development of the Group.

Following the Group's core product, the Toumai Laparoscopic Surgical Robot ("**Toumai**"), receiving over 300 commercial orders worldwide, Toumai has recently been deployed in Spain's leading medical institution, HM Hospitales, completing its 200th commercial installation worldwide. All of these 200 installations have received acceptance reports from the end customers. According to publicly available market statistics, so far this year, Toumai in terms of number of new commercial installations worldwide ranks first among domestic brands and top two globally. The dual milestone breakthroughs in the commercial orders and installations mark the accelerating maturity of Toumai's global clinical ecosystem, real-world application system, and remote collaboration network.

In overseas markets, Toumai continues to rapidly expand its global presence across multiple regions. To date, it has achieved commercial installations in more than 60 countries and regions. Benefiting from scaled commercial installations and the technological leadership in remote surgery, Toumai's brand influence has ranked among the top two globally. As the world's first and only surgical robot system to have received indication for remote surgery in the European Union, Toumai has received orders and is conducting ongoing remote surgery practices in major European countries such as Belgium, Spain, the United Kingdom, Italy, Poland, and Serbia. The Company has accumulated real-world clinical data and practical experience across multiple countries and centres. Among them, Spain has become one of the fastest-growing and most active markets for Toumai in Europe. According to internal statistics, in the first half of 2026 alone, Toumai has completed nearly 10 commercial installations in Spain, and its new installations for the year surpassed those of all other brands, ranking first.

In the PRC market, Toumai has been successfully deployed in four of the top five hospitals in the PRC in terms of comprehensive strength, and has achieved comprehensive coverage across national medical centres, regional medical centres and leading provincial hospitals, with its total installations consistently ranking first among domestic surgical robots.

During its global expansion, the Group has established a global robot surgery ecosystem encompassing equipment deployment, clinical training, professional certification, medical education and full-cycle service support. Through the continuous expansion of its installations and clinical application network, as well as the establishment of nearly 20 clinical and training centres overseas, the Group will accelerate its expansion into more countries, regions and healthcare institutions and continue to drive the commercialisation and application of robot surgery and remote surgery.

The board of directors of the Company wishes to remind the Shareholders and potential investors that the above information is unaudited and is based on preliminary internal information of the Group, which may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of collating such information.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Dr. Zhaohua Chang
Chairman

Shanghai, China, 26 June 2026

As at the date of this announcement, the executive Directors are Dr. Chao He and Mr. Yu Liu, the non-executive Directors are Dr. Zhaohua Chang, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Mr. Chen Chen and Ms. Min Liang, and the independent non-executive Directors are Dr. Guoen Liu, Mr. Jonathan H. Chou, Mr. Haisong Yao and Mr. Wai Man Chung.